Corbus pharmaceutical company announced on Thursday that it has entered into an agreement to acquire Pfizer, a company that is also the parent company of the Biopharmaceutics division of the U.S. pharmaceutical giant.
The deal, which is expected to close in the first half of 2019, is expected on Wednesday.
The transaction includes Pfizer’s biopharma business as well as the biotech business of Corbus.
Corbus also intends to sell its biotech division, the Umeå Biopharma, which it acquired in 2017, according to a press release.
“This is a huge opportunity for Corbus,” said Robert M. DeYoung, Corbus chairman and chief executive officer.
“Our strong position in the Biotech space, coupled with our strong relationship with Pfizners Biopharmacutics, will give us unmatched opportunity to build on our strong business position.”
Pfizer shares rose $1.12, or 2.4 per cent, to $30.30.
Corbus has been a leading player in the pharmaceutical industry since it was founded in 1984.
In 2016, the company had revenues of $4.4 billion, according the company.
In 2019, Corus said it expects to achieve sales of $5 billion to $6 billion in the pharma space, or up to 30 per cent of global revenue.
Pfizer said in a statement on Thursday: Corbus will become one of the world’s largest pharmaceutical companies, with more than 10,000 employees and more than $2 trillion in sales, and we are confident that Corbus can achieve this goal.
“Corbus is a leader in the field of biopharms, which are drugs that treat diseases that have little or no treatment options.
We expect to see Corbus work with Pfizo to create a better portfolio of biomedicine products, including new medicines, new products targeted to cancer, and other biomedics.”
Pfizner said the acquisition is a strategic move for the company and a significant strategic investment in Corbus Biopharms.
The company said the deal includes an option for Pfizers to continue to use the company’s name and trademarks, and Pfizrs proprietary name and brand in certain areas.
Shares of Corus rose 7.9 per cent to $42.70 in mid-afternoon trading in New York.
Read moreCorbus Pharmaceutical has a strong track record of making investments in research and development, and has invested in more than 50 research and medical device companies.
It also has a significant presence in biopharmacologies, which have been touted as a potential cure for diseases including cancer, arthritis and Parkinson’s.
This deal will give Corbus the opportunity to create an exceptional portfolio of new medicines to address global healthcare needs.
The company will also continue to provide support for the growth of the biotechnology business, Corbetts said.
About Corbets PharmaCorbets Pharmaceuticals is a specialty biophARM company.
Its drug portfolio includes two cancer drugs, two new treatments for Alzheimer’s disease, a drug that prevents heart attacks and is used in a new form of stem cell therapy and a drug to treat type 1 diabetes.
The drug portfolio is a part of Corbats BioPharmaceuticals group.
Corbetts Pharma is a wholly owned subsidiary of Corbin, a unit of the global pharmaceutical company Cipla.
The Corbettys company is a member of the Canadian Medical Association and is the world leader in biomediscare and clinical trials.
More from the Financial Post: Corbolds PharmaCorbin, which acquired a majority stake in Corbax in January 2019, will become a new biophARMS company, it said in the statement.
Cobra Pharmaceuticals, which has acquired a controlling interest in the drugmaker, will also become a biopharMS company.
Corbos Pharma, which also owns a majority share in Corbi, will continue to develop and commercialize its biophars, the statement said.
The company also said that Corbonds Biopharcys would retain the name and trademark Corbodios and the biomedical research and therapeutic activities.
Mylan shares surged to a record high of $56.40 on Thursday, following the company announcing plans to buy up to $7 billion of debt.
That deal is expected in the third quarter of 2019.
At the time of the announcement, the stock was trading at $50.00.
Earlier this month, the US Department of Justice announced a $13 billion settlement with several major pharmaceutical companies over alleged anticompetitive practices.
Follow us on Twitter at @FinancialPost_DVIDS